Biomedical and Pharmaceutical Sciences, College of Pharmacy, Kasiska Division of Health Sciences, Pocatello, ID 83209, USA.
School of Chemical Engineering, Yeungnam University, Gyeongsan-si 38541, Korea.
Int J Mol Sci. 2021 Nov 30;22(23):12987. doi: 10.3390/ijms222312987.
Despite the identification of Aβ plaques and NFTs as biomarkers for Alzheimer's disease (AD) pathology, therapeutic interventions remain elusive, with neither an absolute prophylactic nor a curative medication available to impede the progression of AD presently available. Current approaches focus on symptomatic treatments to maintain AD patients' mental stability and behavioral symptoms by decreasing neuronal degeneration; however, the complexity of AD pathology requires a wide range of therapeutic approaches for both preventive and curative treatments. In this regard, this review summarizes the role of receptors as a potential target for treating AD and focuses on the path of major receptors which are responsible for AD progression. This review gives an overall idea centering on major receptors, their agonist and antagonist and future prospects of viral mimicry in AD pathology. This article aims to provide researchers and developers a comprehensive idea about the different receptors involved in AD pathogenesis that may lead to finding a new therapeutic strategy to treat AD.
尽管已经确定 Aβ 斑块和 NFT 是阿尔茨海默病 (AD) 病理学的生物标志物,但仍难以进行治疗干预,目前既没有绝对的预防药物,也没有治疗药物可以阻止 AD 的进展。目前的方法侧重于对症治疗,通过减少神经元变性来维持 AD 患者的精神稳定和行为症状;然而,AD 病理学的复杂性需要广泛的治疗方法来进行预防和治疗。在这方面,本综述总结了受体作为治疗 AD 的潜在靶点的作用,并重点介绍了负责 AD 进展的主要受体途径。本综述围绕主要受体及其激动剂和拮抗剂以及 AD 病理学中病毒模拟的未来前景提供了一个整体思路。本文旨在为研究人员和开发人员提供有关 AD 发病机制中涉及的不同受体的全面认识,这可能有助于找到治疗 AD 的新治疗策略。